抗新型冠状病毒潜力药物——瑞德西韦

Potential Anti 2019-nCoV Drug: Remdesivir

当前,新型冠状病毒(2019-n Co V)感染引发的肺炎疫情已经发展为严重的公共卫生安全问题。针对该病毒,目前临床上并没有针对性的抗病毒药物。瑞德西韦(remdesivir,GS-5734)是由美国吉利德科学公司(Gilead Science)研制的一种新型核苷酸类似物抗病毒药。由于瑞德西韦在抗同属冠状病毒的非典型性肺炎冠状病毒(SARS-Co V)和中东呼吸综合症冠状病毒(MERS-Co V)中表现出较好的作用,一项针对其抗2019-nCoV的临床试验已经在中国启动。本文就该药物的基本信息、作用机制、药动学、国内外研究现状等方面进行概述,以期为临床用药提供参考。

At present,the pneumonia caused by the novel coronavirus(2019-nCoV)infection has developed into a serious public health and safety problem.Currently,there is no targeted antiviral drugs for the virus.Remdesivir(GS-5734)is a new nucleotide analogue antiviral drug developed by Gilead science.The targeted clinical trials against 2019-CoV have been launched in China as remdesivir has shown a good effect in anti SARS-CoV and MERS-CoV.In this paper,the basic information,mechanism of action,pharmacokinetics,research status in domestic and international of remdesivir are summarized in order to provide reference for clinical medication.